NEWSLETTER
RSS
MOBILE
HELP
Theravance, Incorporated (THRX)
SHARE
Email Confirmation
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME
Overview
News
People
Financials
Company Information
Overview
A biopharmaceutical company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction.
News Feeds
-
Targanta shares plummet on negative FDA panel vote
AP
Nov 20 2008
-
FDA panel splits on pair of antibiotics
AP
Nov 19 2008
-
FDA panel: Theravance antibiotic safe, effective
AP
Nov 19 2008
-
Ahead of the Bell: FDA experts review antibiotics
AP
Nov 19 2008
-
FDA notes pregnancy risks with Theravance drug
AP
Nov 17 2008
News From Around the Web
News
-
Nov 20 2008
-
FDA panel splits on pair of antibiotics
(Businessweek)Nov 19 2008 -
Trading in Theravance Common Stock Halted FDA Advisory Committee to Review Telavancin NDA (PharmaLive)Nov 19 2008
-
FDA panel: Theravance antibiotic safe, effective (San Jose Mercury News)Nov 19 2008
-
FDA Panel Backs Theravance's MRSA Antibiotic Telavancin (Morningstar)Nov 19 2008
-
Market Report -- In Play (THRX) (MSN Money)Nov 19 2008
-
Theravance (THRX) Halted For Trading Ahead of FDA Meeting (StreetInsider)Nov 19 2008
-
Ahead of the Bell: FDA experts review antibiotics (Boston Globe)Nov 19 2008
Employees
Number of Employees: 252
Revenue per Employee: $74,744
Top Executives
Dr. Arthur L. Campbell, Ph.D., Divisional Senior VP
Michael W. Aguiar, Senior VP/CFO
Bradford J. Shafer, Senior VP/Secretary/General Counsel
Dr. Mathai Mammen, M.D., Ph.D., Founder/Senior VP, Divisional
David L. Brinkley, Divisional Senior VP
Leonard M. Blum, Senior VP/Other Executive Officer
Board of Directors
Robert V. Gunderson, Jr., J.D., Director
Dr.P. Roy Vagelos, M.D., Founder/Chairman of the Board/Director
Dr.Arnold J. Levine, Ph.D., Director
Bradford J. Shafer, Senior VP/Secretary/General Counsel
Dr.George M. Whitesides, Ph.D., Founder/Director
William H. Waltrip, Director
Financials
Quarterly
Annual
| Income Statement | 10/2008 | 08/2008 | 05/2008 | 03/2008 |
|---|---|---|---|---|
| Sales | 0 | -2.32 Mil. | -1.84 Mil. | -1.53 Mil. |
| Gross Operating Profit | 6 Mil. | 7.82 Mil. | 7.48 Mil. | 7.16 Mil. |
| Operating Income before D & A (EBITDA) | -20.57 Mil. | -19.43 Mil. | -28.46 Mil. | -32.31 Mil. |
| Total Income Before Interest Expenses (EBIT) | -19.41 Mil. | -25.52 Mil. | -28.63 Mil. | -33.24 Mil. |
| Total Net Income | -20.93 Mil. | -27.03 Mil. | -29.76 Mil. | -33.06 Mil. |
| Basic EPS, Total | -0.34 | -0.44 | -0.49 | -0.54 |
| Diluted EPS, Total | -0.34 | -0.44 | -0.49 | -0.54 |
| BALANCE STATEMENT | 10/2008 | 08/2008 | 05/2008 | 03/2008 |
|---|---|---|---|---|
| Cash and Equivalents | 218.84 Mil. | 87.61 Mil. | 81.28 Mil. | 86.43 Mil. |
| Total Assets | 227.73 Mil. | 252.49 Mil. | 268.38 Mil. | 134.09 Mil. |
| Total Liabilities | 19.71 Mil. | 50.17 Mil. | 49.72 Mil. | 55.53 Mil. |
| Total Capitalization | 47.35 Mil. | 61.25 Mil. | 82.31 Mil. | -65.83 Mil. |
| Cash Flow | 10/2008 | 08/2008 | 05/2008 | 03/2008 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | NA | -64.14 Mil. | -35.8 Mil. | -104.37 Mil. |
| Net Cash From Investing Activities | NA | -104.22 Mil. | -136.27 Mil. | 110.59 Mil. |
| Net Cash From Financing Activities | NA | 169.53 Mil. | 166.92 Mil. | 7.82 Mil. |
| Net Change in Cash & Cash Equivalents | NA | 1.18 Mil. | -5.15 Mil. | 14.04 Mil. |
| Income Statement | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Sales | -4.06 Mil. | -4.2 Mil. | -4.11 Mil. | -4.81 Mil. |
| Gross Operating Profit | 26.06 Mil. | 23.78 Mil. | 16.16 Mil. | 13.75 Mil. |
| Operating Income before D & A (EBITDA) | -164.51 Mil. | -174.97 Mil. | -145.45 Mil. | -101.58 Mil. |
| Total Income Before Interest Expenses (EBIT) | -159.9 Mil. | -165.52 Mil. | -142.59 Mil. | -101.83 Mil. |
| Total Net Income | -160 Mil. | -166.04 Mil. | -143.16 Mil. | -102.65 Mil. |
| Basic EPS, Total | -2.64 | -2.81 | -2.69 | -3.08 |
| Diluted EPS, Total | -2.64 | -2.81 | -2.69 | -3.08 |
| BALANCE STATEMENT | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Cash and Equivalents | 86.43 Mil. | 72.39 Mil. | 49.79 Mil. | 101.41 Mil. |
| Total Assets | 134.09 Mil. | 207.17 Mil. | 166.82 Mil. | 264.47 Mil. |
| Total Liabilities | 55.53 Mil. | 59.61 Mil. | 48.17 Mil. | 35.04 Mil. |
| Total Capitalization | -65.83 Mil. | 63.85 Mil. | 60.22 Mil. | 191.07 Mil. |
| Cash Flow | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | -104.37 Mil. | -104.79 Mil. | -58.64 Mil. | -47.82 Mil. |
| Net Cash From Investing Activities | 110.59 Mil. | -18.58 Mil. | 3.34 Mil. | -100.37 Mil. |
| Net Cash From Financing Activities | 7.82 Mil. | 145.97 Mil. | 3.68 Mil. | 213.85 Mil. |
| Net Change in Cash & Cash Equivalents | 14.04 Mil. | 22.6 Mil. | -51.62 Mil. | 65.66 Mil. |
Related Companies by Market Cap
Company Name
Price
Change
Market Cap
1.11 Bil.
1.17 Bil.
1.26 Bil.
1.27 Bil.
Company Profile Change Request
The data provided in our company profiles comes from third party information providers.- To request a change please click here
Also in Portfolio.com
Most Read
Most Emailed
Recently Commented
TOP 5
(Daily)
A smart take on the top stories shaping the business world.
Executives & Careers
(Tuesdays)
A weekly guide to the personalities and ideas that are transforming the business world.
Inside Portfolio.com
(Wednesdays)
Our roundup of the week's best from Portfolio.com.
Culture & Lifestyle
(Fridays)
A weekly guide to the best ways to spend your time - and money.
In This Issue
(Monthly)
Be the first to know when the latest issue of Condé Nast Portfolio magazine is online.
RSS Most Read
Mobile